Barclays lowered the firm’s price target on Avantor (AVTR) to $23 from $26 and keeps an Overweight rating on the shares post the Q4 report. The ...

What Are the Key Developments Surrounding Avantor (NYSE:AVTR)?

Companies in the Materials sector have received a lot of coverage today as analysts weigh in on EMS-CHEMIE HOLDING AG (EMSHF – Research ...

We recently compiled a list of the 10 Companies Echo Friday’s Market Pessimism. In this article, we are going to take a look ...

Analysts at Zacks Research reduced their Q1 2025 earnings per share estimates for Avantor in a research report issued to ...

In the fiscal year ended December 31, 2024, Avantor recorded net sales of $6,783.6 million, net income of $711.5 million, ...

Michael Stubblefield, CEO, highlighted Avantor's return to growth in Q4 2024 with low single-digit organic growth and strong bioprocessing performance, achieving high single-digit organic growth in ...

Avantor's Q4 net sales missed estimates, but adjusted EPS beat expectations. The company projects 2025 organic revenue growth ...

Avantor, Inc. (AVTR) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.25 per share a year ago. These ...

Life sciences company Avantor (NYSE:AVTR) fell short of the market’s revenue expectations in Q4 CY2024, with sales falling ...

Avantor recorded slightly lower sales in its fourth quarter due to unfavorable foreign exchange rates, though its earnings were boosted by a divestiture. The biopharma supplier posted a profit of $500 ...